RecruitingNCT02732860

Personalized Patient Derived Xenograft (pPDX) Modeling to Test Drug Response in Matching Host

Prospective Evaluation of Freshly Implanted Cancers in Mice to Test Drug Response in Matching Host

Sponsor

University Health Network, Toronto

Enrollment

120 participants

Start Date

Dec 1, 2015

Study Type

OBSERVATIONAL

Conditions

Colorectal Neoplasms

Summary

By obtaining clinical specimens from participants with triple negative breast cancer (TNBC), colorectal cancer (CRC), high grade serous ovarian cancer (HGSOC), and other select tumor types to establish and profile as freshly implanted tumors in mice, the aim of this study is to identify agents with predicted activity in the host patient while also potentially providing them with personalized cancer treatment options

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study grows a miniature version of a patient's tumor in mice (called a patient-derived xenograft model) to test which cancer drugs work best against it, then uses that information to guide treatment for that specific patient. **You may be eligible if...** - You are 18 or older - You have triple-negative breast cancer (stage IV, or with remaining tumor after pre-surgery chemotherapy), stage IV colorectal cancer, ovarian cancer, or another solid tumor that has spread and has exhausted standard treatment options - You have tumor tissue available for laboratory testing - You are well enough to undergo a tissue biopsy **You may NOT be eligible if...** - You are not well enough to tolerate a biopsy - There is no accessible tumor tissue for collection - You are pregnant or breastfeeding - You have other serious health conditions that would make participation unsafe Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERMolecular Profiling & In Vivo drug testing in pPDX and organoid cultures

Molecular profiling of host tumour sample and pPDX will be performed and analyzed by an expert panel. In vitro organoid culture generation may also be performed if sufficient fresh tissue is available. Matched treatment recommendation based on profiling and in vivo pPDX drug testing results will be made, if available. This recommendation will be communicated to the primary oncologist.